Submitted by Anonymous on Tue, 03/31/2015 - 11:06
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Jonathan W Friedberg, MD, MMSc (1/8/15)
Sharman J et al. Second interim analysis of a phase 3 study of idelalisib (Zydelig) plus rituximab for relapsed chronic lymphocytic leukemia: Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Proc ASH 2014;Abstract 330.
Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.
